ELOX - エロックス・ファ―マシュ―ティカルズ (Eloxx Pharmaceuticals Inc.) エロックス・ファ―マシュ―ティカルズ

 ELOXのチャート


 ELOXの企業情報

symbol ELOx
会社名 Eloxx Pharmaceuticals Inc (エロックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Eloxx Pharmaceuticals Inc. formerly Sevion Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The Company’s lead product candidate is ELX-02 is an optimized aminoglycoside designed to restore full-length functional proteins. The ELX-02 which is in Phase I clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. As part of clinical program the Company has completed a Phase Ia single ascending dose study in Israel and Belgium. The Company also intends to advance one or more additional molecules from its drug product candidate library toward clinical development.   エロックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がんや免疫疾患に対する治療の開発・商業化に従事する。同社候補薬は細胞ベ―スのアレイ化抗体やキメラソ―ム・ナノケ―ジを含む。また、免疫疾患や炎症性疾患の病因であるKv1.3イオンチャネルや、がんの進行に関する分子を標的とする治療を開発する。本社はマサチュ―セッツ州ウォルサム。   Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ.
本社所在地 950 Winter Street Waltham MA 02451 USA
代表者氏名 Robert E. Ward ロバートE.ウォード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 858-909-0749
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 15人
url www.senesco.com
nasdaq_url https://www.nasdaq.com/symbol/elox
adr_tso
EBITDA EBITDA(百万ドル) -40.95794
終値(lastsale) 14.91
時価総額(marketcap) 519728008.8
時価総額 時価総額(百万ドル) 522.51660
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 459.10460
当期純利益 当期純利益(百万ドル) -41.16942
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eloxx Pharmaceuticals Inc revenues was not reported. Net loss totaled to $22M. Results are not comparable due to year end change.

 ELOXのテクニカル分析


 ELOXのニュース

   Blustering Stock Grabbing Investors Attention: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), Alibaba Group Holding Limited (NYSE:BABA)  2021/12/20 00:07:31 Stock Equity
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) with the stream of 12.06% also noticed, India Alibaba Group Holding Limited (NYSE:BABA) encountered a rapid change of 1.54% in the last hour of Fridays trading The post Blustering Stock Grabbing Investors Attention: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), Alibaba Group Holding Limited (NYSE:BABA) appeared first on Stocks Equity .
   Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Oppenheimer  2021/12/18 06:56:44 Transcript Daily
Investment analysts at Oppenheimer began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Thursday, Price Targets.com reports. The brokerage set an outperform rating and a $4.00 price target on the stock. Oppenheimers price target suggests a potential upside of 441.27% from the stocks previous close. ELOX has been the []
   Glistering Stock: Sunworks, Inc. (NASDAQ:SUNW), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/16 00:30:26 Stock Equity
Sunworks, Inc. (NASDAQ:SUNW) with the stream of 3.22% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of 3.74% in the last hour of Wednesdays trading session. Sunworks, The post Glistering Stock: Sunworks, Inc. (NASDAQ:SUNW), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Millennium Management LLC Makes New Investment in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/13 09:24:42 Transcript Daily
Millennium Management LLC acquired a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 393,703 shares of the companys stock, valued at approximately $783,000. Millennium Management LLC owned approximately 0.82% of Eloxx Pharmaceuticals at the end of the []
   Top RSI Trades for the day: New Oriental Education & Technology Group Inc. (NYSE:EDU), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/12 23:28:46 Stock Equity
New Oriental Education & Technology Group Inc. (NYSE:EDU) with the stream of 4.07% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of -5.41% in the last hour The post Top RSI Trades for the day: New Oriental Education & Technology Group Inc. (NYSE:EDU), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Traders cant mares this Stock: NIO Inc. (NYSE:NIO), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/07/27 22:29:48 Stock Equity
NIO Inc. (NYSE:NIO) with the stream of -8.91% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of 2.22% in the last hour of Tuesdays trading session. NIO The post Traders cant mares this Stock: NIO Inc. (NYSE:NIO), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Global Duchenne Muscular Dystrophy Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Akashi Therapeutics Inc, Capricor Therapeutics Inc, Biogen Inc, Antisense Therapeutics Ltd, Biophytis SAS, Beech Tree Labs Inc, CRISPR Therapeutics, BioMarin Pharmaceutical Inc, Bioleaders Corp, Catabasis Pharmaceuticals Inc, Eloxx Pharmaceuticals Inc, Fulcrum Therapeutics In  2021/07/24 00:25:49 Jumbo News
The report on Global Duchenne Muscular Dystrophy Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   Analyzing Analysts Recommendations: Moderna, Inc. (NASDAQ:MRNA), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/07/14 21:09:36 Stock Equity
Moderna, Inc. (MRNA) with the stream of 5.15% also noticed, India Eloxx Pharmaceuticals, Inc. (ELOX) encountered a rapid change of -1.90% in the last hour of Wednesdays trading session. Moderna, The post Analyzing Analysts Recommendations: Moderna, Inc. (NASDAQ:MRNA), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021  2021/07/07 12:04:45 Benzinga
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) provided an enrollment update for the ongoing Phase 2 trial of ELX-02 to treat cystic fibrosis (CF) in patients with at least one G542X allele. Based on enrollment to date, Eloxx expects to present data from the first four treatment arms in Q4 of 2021. As of the end Full story available on Benzinga.com
   Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition  2021/04/01 13:08:10 Benzinga
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) has acquired Zikani Therapeutics Inc in an all-stock transaction . The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare diseases and oncology. Sumit Aggarwal, previously the President and CEO of Zikani, has been named President and CEO of Eloxx. Vijay Modur, Zikani's Chief Scientific and Medical Officer, has been named … Full story available on Benzinga.com
   Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS  2021/03/12 23:21:18 Transcript Daily
Eloxx Pharmaceuticals (NASDAQ:ELOX) announced its quarterly earnings results on Wednesday. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.07, Fidelity Earnings reports. Shares of Eloxx Pharmaceuticals stock traded up $0.20 during mid-day trading on Friday, hitting $4.07. 108,169 shares of the stock were exchanged, […]
   CF Foundation Awards Up to $2M to Eloxx Pharmaceuticals for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations  2021/01/13 14:00:00 Business Wire
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations. In 2019, the Foundation provided Eloxx with an award of up to $1.6 million to support the development of ELX-02 in the U.S. This additional funding will provide continued support for a Phase 2 proof-of-concept cli
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Stocks News Feed  2020/11/18 16:30:00 Stocks News Feed
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx,… Read More »Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エロックス・ファ―マシュ―ティカルズ ELOX Eloxx Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)